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Sjögren-Larsson syndrome (SLS) is an autosomal reces-
sive disorder characterized by ichthyosis, spastic diple-
gia or tetraplegia and intellectual disability. Ichthyosis 
largely develops early in life. The neonatal skin has an 
erythrodermic appearance that gradually evolves into a 
generalized ichthyosiform hyperkeratosis during infancy, 
which is most prominent in the flexural areas. Ichthyo-
sis in SLS has a striking pruritic character, resulting in 
excoriations and scaling (1).
SLS is caused by a deficiency of microsomal fatty 
aldehyde dehydrogenase (FALDH), resulting in distur-
bed lipid metabolism (2). Lipid metabolism plays an 
important part in the normal formation of the water bar-
rier in the stratum corneum. In patients with SLS, lamel-
lar bodies, synthesized in the stratum granulosum and 
normally containing essential precursor membranes, are 
misshapen and empty. To restore barrier function, the 
skin reacts by hyperkeratosis, resulting in ichthyosis (3). 
The pruritus may also have another pathophysio-
logical origin. Previously, we showed an association 
between pruritus and elevation of pro-inflammatory 
leukotriene B4 (LTB4), which is also FALDH-depen-
dent for its breakdown (4). This association was later 
confirmed in experimental studies in mice (5). In SLS, 
elevation of dermal LTB4, by increased production, 
defective breakdown, or a combination of both, proba-
bly plays an important role in the pruritus. Zileuton is 
an oral drug that blocks the formation of leukotrienes 
(including LTB4) from arachidonic acid. 
Previously, we studied zileuton treatment in a non-place-
bo controlled study and found some beneficial effects on 
pruritus (6, 7). To further investigate the potential effects 
of zileuton, we performed this randomized controlled trial.
METHODS (See Appendix S11)
RESULTS
Included patients (n = 10; age range 7–40 years, equal 
sex distribution) were randomized to 1 of 2 treatment 
arms with either zileuton (dosage as for asthma) or 
placebo in 2 periods of 8 weeks, separated by a wash-
out period of 4 weeks.
Except for small effects on severity scores Sjögren-
Larsson Severity Index (SLaSI) for desquamation and 
Physician Global Assessment (PGA) scores in the se-
cond treatment period, changes in mean scores were not 
significantly different between the zileuton and placebo 
groups. However, when analysing individual results, 
patient No. 4 (an 8-year-old girl), responded on zileu-
ton treatment (400 mg 4 times a day) with substantial 
changes in almost every scoring item (Table I).
Regarding secondary outcome measures, large 
intra-individual variability in pruritus VAS 
scores was seen in subsequent study weeks 
in some patients in both the treatment and 
the placebo period. There was also signifi-
cant inter-individual variability in scores, 
illustrating differences in SLS phenotype. 
Substantial decreases in mean VAS scores 
were detected in only patient No. 4. Retro-
spective analysis of the medical records 
from all patients showed that, for this pa-
tient, only the parents reported a tremendous 
clinical improvement, especially regarding 
pruritus only, in the period when zileuton 
was administered. A complete setback was 
reported within days after discontinuation 
of zileuton at the wash-out visit. 
For unknown reasons, measurement of 
baseline urinary concentrations of LTB4 and 
20-OH-LTB4, failed to detect the expected 
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Table I. Individual responders’ analysis
Patient
SLaSI
PGA
VAS
Ery-
thema
Desqua-
ma tion
Licheni-
fication
Excoria-
tions Pruritus
Excoria-
tions
Total  
score
Re-
sponder
1 – – 0.75 1.25 – – – 2 –
2 0.5 – 0.5 1.0 1.0 – – 4 –
3 – 1.0 – 1.25 2.0 – – 3 –
4 – 1.0 0.75 0.75 2.0 + + 6 +
5 – 0.75 0.5 – 1.0 – – 3 –
6 – 2.0 1.0 – 1.0 – – 3 –
7 – – – – – – – 0 –
8 – – – – – – – 0 –
9 0.75 – – – – – – 1 –
10 – – – 0.75 – – – 1 –
Sjögren-Larsson Severity Index (SLaSI) and Physician Global Assessment (PGA) outcomes 
in individuals: sum of SLaSI mean score before zileuton treatment minus SLaSI mean score 
after zileuton treatment. Results are only given if sum was ≥ 0.5; otherwise the patient is 
considered a non-responder (–). Visual analogue scale (VAS) outcomes: positive score if 
difference in mean VAS scores during the treatment and placebo periods was ≥20 mm. Patient 
is considered to be a responder to zileuton treatment if the total score was ≥5.
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differences in LTB4 and 20-OH-LTB4 excretion bet-
ween SLS patients and healthy controls. Biochemical 
responses to treatment could thus not be confirmed 
(including the only responding patient). No adverse 
events related to the study drug were observed.
DISCUSSION
This study could only detect convincing clinical effects 
of zileuton treatment in one patient. Upon parental re-
quest, the patient continued zileuton and was monitored 
closely. Follow-up (~1 year) after the study showed 
a consistent beneficial therapeutic effect. From the 
patients studied previously, 2 other patients still use 
zileuton with lasting beneficial effects. The reason why 
only a few patients respond to treatment is unknown. 
Although genotypes in SLS differ, the corresponding 
clinical phenotype and degree of enzyme deficiency are 
usually quite homogeneous, making it impossible to pre-
dict responders. The 3 responders from these 2 studies have 
different genotypes and lack residual FALDH activity. 
Also, amongst the non-responders in this trial there were 
patients with the same genotype as the responding patient.
Furthermore, intellectual disability in SLS patients 
may result in scratching becoming habitual behaviour. 
Therefore, scratching may continue even when the 
pruritus is reduced by zileuton treatment, disguising 
potential beneficial effects. Due to unsuccessful urinary 
leukotriene analysis, we could not confirm biochemi-
cally that exposure to zileuton in this study was suf-
ficient to decrease leukotriene production.
Epidermal LTB4 is produced by keratinocytes upon 
stimulation of specific receptors (5). Research in mice 
proved that orally administered zileuton has the ability 
to inhibit epidermal LTB4 production and decrease 
pruritus (11). However, correlations between zileuton 
dosages used in animal research and the dosages used 
in this study are unclear. 
Use of zileuton in SLS is off-label, and no formal dose-
finding studies have been performed. Dosages used were 
based on the treatment of asthma, in which leukotrienes 
are formed by mast cells that may have different bioche-
mical responses to zileuton than keratinocytes (12). In 
addition, it is possible that dosages of zileuton in SLS 
should be higher than used here to sufficiently penetrate 
epidermal layers or have stronger inhibitory effects on 
leukotriene formation. Also, it is possible that pharmaco-
genetics play a part in the heterogeneous inter-individual 
response to treatment with leukotriene-modifiers (13). 
Based on findings from our study it appears that 
only a few patients with SLS will benefit from zileuton 
treatment. However, responders can easily be detec-
ted clinically and will experience an improvement in 
quality of life. Therefore, when medical treatment for 
severe pruritus is warranted in SLS patients ≥ 5 years, a 
therapeutic trial with zileuton for a period of 4–6 weeks 
still may be considered. If no clear beneficial response 
to zileuton is noted, treatment should be discontinued. 
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